410 related articles for article (PubMed ID: 11123269)
1. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.
Zhang J; Roschke V; Baker KP; Wang Z; Alarcón GS; Fessler BJ; Bastian H; Kimberly RP; Zhou T
J Immunol; 2001 Jan; 166(1):6-10. PubMed ID: 11123269
[TBL] [Abstract][Full Text] [Related]
2. [B lymphocyte stimulator (BLyS) and monocytes: possible role in autoimmune diseases with a particular reference to rheumatoid arthritis].
Quartuccio L; Fabris M; Ferraccioli G
Reumatismo; 2004; 56(3):143-6. PubMed ID: 15470519
[TBL] [Abstract][Full Text] [Related]
3. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
[TBL] [Abstract][Full Text] [Related]
4. SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder.
Stohl W
Arthritis Res Ther; 2003; 5(3):136-8. PubMed ID: 12723979
[TBL] [Abstract][Full Text] [Related]
5. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.
Roschke V; Sosnovtseva S; Ward CD; Hong JS; Smith R; Albert V; Stohl W; Baker KP; Ullrich S; Nardelli B; Hilbert DM; Migone TS
J Immunol; 2002 Oct; 169(8):4314-21. PubMed ID: 12370363
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
Cheema GS; Roschke V; Hilbert DM; Stohl W
Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690
[TBL] [Abstract][Full Text] [Related]
8. BLyS levels in sera of patients with systemic lupus erythematosus: clinical and serological correlation.
Elbirt D; Asher I; Mahlab-Guri K; Bezalel-Rosenberg S; Edelstein V; Sthoeger Z
Isr Med Assoc J; 2014 Aug; 16(8):491-6. PubMed ID: 25269340
[TBL] [Abstract][Full Text] [Related]
9. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders.
Stohl W
Expert Opin Ther Targets; 2004 Jun; 8(3):177-89. PubMed ID: 15161425
[TBL] [Abstract][Full Text] [Related]
10. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Roschke V; Wu Y; Baker KP; Hilbert DM
Ann Rheum Dis; 2004 Sep; 63(9):1096-103. PubMed ID: 15308519
[TBL] [Abstract][Full Text] [Related]
11. A therapeutic role for BLyS antagonists.
Stohl W
Lupus; 2004; 13(5):317-22. PubMed ID: 15230285
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
13. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
Stohl W
Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
[TBL] [Abstract][Full Text] [Related]
14. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein.
Stohl W
Curr Opin Rheumatol; 2002 Sep; 14(5):522-8. PubMed ID: 12192248
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of BLyS action in B cell immunity.
Do RK; Chen-Kiang S
Cytokine Growth Factor Rev; 2002 Feb; 13(1):19-25. PubMed ID: 11750877
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
[TBL] [Abstract][Full Text] [Related]
17. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes.
López P; Scheel-Toellner D; Rodríguez-Carrio J; Caminal-Montero L; Gordon C; Suárez A
Rheumatology (Oxford); 2014 Dec; 53(12):2249-58. PubMed ID: 24942493
[TBL] [Abstract][Full Text] [Related]
18. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.
Moore PA; Belvedere O; Orr A; Pieri K; LaFleur DW; Feng P; Soppet D; Charters M; Gentz R; Parmelee D; Li Y; Galperina O; Giri J; Roschke V; Nardelli B; Carrell J; Sosnovtseva S; Greenfield W; Ruben SM; Olsen HS; Fikes J; Hilbert DM
Science; 1999 Jul; 285(5425):260-3. PubMed ID: 10398604
[TBL] [Abstract][Full Text] [Related]
19. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
20. BLyS and B cell autoimmunity.
Zhou T; Zhang J; Carter R; Kimberly R
Curr Dir Autoimmun; 2003; 6():21-37. PubMed ID: 12408045
[No Abstract] [Full Text] [Related]
[Next] [New Search]
